trending Market Intelligence /marketintelligence/en/news-insights/trending/100_yadbmdsnx8-udqadya2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Adaptimmune raises $100M in offering of American depositary shares

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Adaptimmune raises $100M in offering of American depositary shares

Adaptimmune Therapeutics PLC sold 10 million American depositary shares at $10 apiece in a registered direct offering, raising net proceeds of about $100 million.

The U.K.-based biopharmaceutical company will use the proceeds to further develop its pipeline of specific peptide enhanced affinity receptor T-cell candidates through clinical trials.

Adaptimmune is currently developing its drug candidates MAGE-A4, MAGE-A10 and AFP to treat multiple solid tumor indications.

The company will also use a portion of the proceeds for other general corporate purposes.

Matrix Capital Management Co. LP, New Enterprise Associates 16 LP, New Enterprise Associates 14 LP and Syncona Portfolio Ltd. participated in the transaction.